Related Experiment Video
Updated: Apr 18, 2026
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
Published on: March 14, 2020
The challenges of liver transplantation in children with primary sclerosing cholangitis
Veena L Venkat1, Sarangarajan Ranganathan, Rakesh Sindhi
1Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Pittsburgh of UPMC, Pediatrics, 4401 Penn Avenue, Pittsburgh, PA 15224, USA.
Insights
Primary sclerosing cholangitis (PSC) in children presents significant challenges, potentially leading to liver failure. Research in pediatric PSC and post-transplant outcomes offers unique insights into this rare autoimmune liver disease.
Area of Science:
- Pediatric gastroenterology and hepatology
- Autoimmune liver diseases
- Transplant medicine
Background:
- Primary sclerosing cholangitis (PSC) in children can advance to end-stage liver disease, necessitating liver transplantation.
- PSC management is complex, involving diagnostic challenges, limited medical options, and specific post-transplant risks.
- While associations with autoimmunity exist (autoantibodies, IBD, HLA linkage), PSC does not respond to standard immunosuppression.
Purpose of the Study:
- To highlight the challenges in evaluating and managing pediatric primary sclerosing cholangitis.
- To explore the potential of studying PSC and post-transplant outcomes in children to understand this disease better.
- To investigate the role of genetic susceptibility and immune dysregulation in early-onset PSC.
Main Methods:
- Review of existing literature on pediatric PSC and liver transplantation.
- Analysis of clinical data from children diagnosed with PSC, particularly those diagnosed within the first decade of life.
- Discussion of the need for long-term, multicenter studies.
Main Results:
- Pediatric PSC presents unique diagnostic and therapeutic hurdles.
- Early-onset PSC in children suggests a strong genetic and immune basis.
- Post-transplant outcomes in pediatric PSC patients offer valuable research avenues.
Conclusions:
- Studying pediatric PSC and its post-transplant course is crucial for advancing knowledge of this rare autoimmune liver disease.
- Collaborative, long-term research efforts are essential to improve outcomes for children with PSC.
- Understanding genetic and immune factors is key to developing effective treatments.
Abstract:
Primary sclerosing cholangitis (PSC) in children can progress to end-stage liver disease requiring liver transplantation. PSC poses many challenges beginning with evaluation and classification of ductal involvement and overlap syndromes, few options for medical management and unique risks in the post-transplant period. The construct that PSC may be an autoimmune disease is based on positive autoantibodies, association with inflammatory bowel disease, linkage to HLA type and overlap/autoimmune sclerosing cholangitis; however, PSC is not responsive to standard immunosuppression. Study of PSC and post-transplant outcomes in children may provide a unique background in which to study this challenging disease. This is particularly intriguing in the subset of patients diagnosed in the first decade of life, suggesting a strong link to predisposing genetic susceptibility and immune dysregulation. Long-term, multicenter effort is likely to be the only mechanism to study this rare disease in children and to improve outcomes in the future.
